Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cantor Fitzgerald
Colorcon
Teva
UBS
Covington

Generated: April 19, 2019

DrugPatentWatch Database Preview

INFUGEM Drug Profile

« Back to Dashboard

When do Infugem patents expire, and when can generic versions of Infugem launch?

Infugem is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. There is one patent protecting this drug.

This drug has seventeen patent family members in fourteen countries.

The generic ingredient in INFUGEM is gemcitabine hydrochloride. There are thirty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the gemcitabine hydrochloride profile page.

Summary for INFUGEM
International Patents:17
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Prior Art and Litigation SupportOrder Prior Art and Litigation support for INFUGEM
DailyMed Link:INFUGEM at DailyMed
Drug patent expirations by year for INFUGEM

US Patents and Regulatory Information for INFUGEM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Ltd INFUGEM gemcitabine hydrochloride SOLUTION;INTRAVENOUS 208313-001 Jul 16, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Sun Pharm Inds Ltd INFUGEM gemcitabine hydrochloride SOLUTION;INTRAVENOUS 208313-007 Jul 16, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Sun Pharm Inds Ltd INFUGEM gemcitabine hydrochloride SOLUTION;INTRAVENOUS 208313-004 Jul 16, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Sun Pharm Inds Ltd INFUGEM gemcitabine hydrochloride SOLUTION;INTRAVENOUS 208313-008 Jul 16, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for INFUGEM

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0122707 96C0030 Belgium ➤ Try a Free Trial PRODUCT NAME: CHLORHYDRATE DE GEMCITABINE EQUIVALENT EN GEMCITABINE; NAT. REGISTRATION NO/DATE: 58 IS 88 F 12 19960606; FIRST REGISTRATION: NL RVG 17854 19950327
0122707 SPC/GB95/031 United Kingdom ➤ Try a Free Trial PRODUCT NAME: GEMCITABINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY- ACCEPTABLE SALT; REGISTERED: NL RVG17854 19950327; UK 00006/0301 19951026; UK 00006/0302 19951026
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Citi
Cantor Fitzgerald
McKesson
AstraZeneca
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.